The effects of menopausal vasomotor symptoms and changes in anthropometry on breast cancer etiology by Hart, Victoria
University of Massachusetts Amherst 
ScholarWorks@UMass Amherst 
Doctoral Dissertations Dissertations and Theses 
Spring March 2015 
The effects of menopausal vasomotor symptoms and changes in 
anthropometry on breast cancer etiology 
Victoria Hart 
University of Massachusetts - Amherst 
Follow this and additional works at: https://scholarworks.umass.edu/dissertations_2 
 Part of the Epidemiology Commons 
Recommended Citation 
Hart, Victoria, "The effects of menopausal vasomotor symptoms and changes in anthropometry on breast 
cancer etiology" (2015). Doctoral Dissertations. 301. 
https://scholarworks.umass.edu/dissertations_2/301 
This Open Access Dissertation is brought to you for free and open access by the Dissertations and Theses at 
ScholarWorks@UMass Amherst. It has been accepted for inclusion in Doctoral Dissertations by an authorized 
administrator of ScholarWorks@UMass Amherst. For more information, please contact 
scholarworks@library.umass.edu. 
  
 
 
 
 
 
 
 
 
 
 
 
 
THE EFFECTS OF MENOPAUSAL VASOMOTOR SYMPTOMS AND CHANGES IN 
ANTHROPOMETRY ON BREAST CANCER ETIOLOGY 
 
 
 
 
 
 
 
 
A Dissertation Presented 
 
 
by 
 
VICTORIA HART 
 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate School of the 
University of Massachusetts Amherst in partial fulfillment 
of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
February 2015 
 
Public Health 
Biostatistics and Epidemiology 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by Victoria Hart 2015 
 
All Rights Reserved 
 
  
 
 
 
 
 
 
THE EFFECTS OF MENOPAUSAL VASOMOTOR SYMPTOMS AND CHANGES IN 
ANTHROPOMETRY ON BREAST CANCER ETIOLOGY 
 
 
 
 
 
 
 
 
A Dissertation Presented 
 
by 
 
VICTORIA HART 
 
 
 
 
 
 
Approved as to style and content by: 
 
 
 _________________________________________  
Katherine W. Reeves, Chair 
 
 
 _________________________________________  
Susan R. Sturgeon, Member 
 
 
 _________________________________________  
Nicholas G. Reich, Member 
 
 
 _________________________________________  
Lynnette Leidy Sievert, Member 
 
 
 ______________________________________  
Paula Stamps, Graduate Program Director 
Public Health 
 
 iv 
ACKNOWLEDGMENTS 
 
I would like to thank Dr. Katherine Reeves for her mentorship and support during this process.  I 
am most grateful for her generous time and guidance.  I would also like to thank Dr. Susan 
Sturgeon, Dr. Nicholas Reich, and Dr. Lynnette Leidy Sievert for their thoughtful critique and 
contribution to this work.  I appreciate the support of Dr. Brian Sprague and the many learning 
opportunities that he has provided for me throughout this process.  I am also indebted to our 
collaborators at the SWAN and BCSC facilities for their interest in and efforts towards this 
research. 
 
I would like to thank my family - Mum, Dad, Chris, Chris, and Ruby - for their care, their 
encouragement, and their belief in my success.  I am more than grateful for everything you have 
given me. 
 
Finally, I would like to thank my friend family - you know who you are - for the many miles, 
many bottles of wine, and many moments of support.  This would not have been possible without 
you. 
 
 
  
 v 
ABSTRACT 
THE EFFECTS OF MENOPAUSAL VASOMOTOR SYMPTOMS AND CHANGES IN 
ANTHROPOMETRY ON BREAST CANCER ETIOLOGY 
 
FEBRUARY 2015 
 
VICTORIA HART 
 
B.S., CORNELL UNIVERSITY 
 
M.S., UNIVERSITY OF VERMONT 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Katherine W. Reeves 
 
 
 Much about the etiology of breast cancer remains unknown.  One of the strongest 
predictors of breast cancer risk is mammographic density; however, the mechanisms relating 
density to breast cancer risk are not fully understood and this has limited the use of 
mammographic density as a marker for breast cancer susceptibility.   Hormone fluctuations 
during the menopausal transition may influence declines in mammographic density and may also 
trigger the onset of menopausal vasomotor symptoms (VMS), which have been associated with 
lower breast cancer risk.  The effects of hormone changes on density, VMS, and ultimately breast 
cancer risk are complicated by external factors such as changing body mass and exogenous 
hormone therapy use during the menopausal transition. 
 We evaluated the longitudinal association between change in BMI and change in breast 
density among 24,556 women in the Breast Cancer Surveillance Consortium using a novel 
volumetric measurement method.  We found that an annual increase in BMI was associated with 
a decrease in both absolute dense volume (β=-1.01 cm3, 95% CI -1.59, -0.42) and in percent 
dense volume (β=-1.17%, 95% CI -1.31, -1.04).  Longitudinal studies of density and breast 
cancer, or those using density to reflect breast cancer risk, should thus consider controlling for 
BMI gain/loss to understand the independent relationship between density and risk.  We further 
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investigated the association of VMS and percent mammographic density (PMD) among 833 
women enrolled Study of Women’s Health Across the Nation (SWAN) Mammographic Density 
Sub-study.  We observed no overall association between VMS and PMD (β = -0.47%, 95% CI -
1.39, 0.45), although some evidence of an inverse association was found among perimenopausal 
women (β = -1.29%, 95% CI -2.58, -0.001) and those using hormone therapy (β = -3.62%, 95% 
CI -7.17, -0.07).  These results suggest that an association between VMS and breast cancer risk is 
via a pathway that is not strongly mediated by changes in breast density.  Finally, we evaluated 
VMS and incident breast cancer risk within the full SWAN cohort of 3,098 women.  VMS were 
associated with a 38% reduction in breast cancer risk (OR 0.62, 95% CI 0.39, 0.99).  Adjustment 
for endogenous hormone levels in this analysis did not alter our results, suggesting that 
endogenous hormones may play a lesser role in the observed association between VMS and 
breast cancer risk than has been previously hypothesized. 
 The results of these studies further our understanding of breast cancer etiology.  If 
confirmed, the association between VMS and breast cancer risk could propose VMS as an easily 
measured factor that may be used to enhance risk prediction in clinical practice.  Our findings that 
this association is not strongly mediated through breast density nor endogenous hormone levels 
raise provocative questions regarding the biological mechanisms that may link VMS to breast 
cancer risk.  Extending our knowledge of breast cancer etiology using new measurement methods 
and novel risk factors may lead to improved risk prediction and provide opportunities for disease 
prevention. 
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CHAPTER 1 
 
THE EFFECT OF WEIGHT CHANGE ON VOLUMETRIC MEASURES OF 
MAMMOGRAPHIC DENSITY: A LONGITUDINAL STUDY IN THE BREAST 
CANCER SURVEILLANCE CONSORTIUM 
1.1 Abstract 
The impact of changing body mass index (BMI) on breast composition is unclear.  The 
association between BMI and breast density is important in evaluating adjustment for BMI 
gain/loss in longitudinal studies of density and breast cancer risk.  In cross-sectional analysis, 
BMI has been associated with lower dense breast area but higher dense breast volume.  No 
studies to date have explored a longitudinal association using volumetric methods to assess 
density. 
We examined the association between change in BMI and change in volumetric density 
in a population of 24,556 women who received breast imaging at the San Francisco site of the 
Breast Cancer Surveillance Consortium from 2007-2013.  Height and weight were self-reported 
at the time of the mammogram.  Breast density was assessed using single x-ray absorptiometry 
(SXA) volumetric measurement.  The cross-sectional and longitudinal associations between BMI 
and absolute dense volume (DV), absolute non-dense volume (NDV) and percent dense volume 
(PDV) were assessed using multivariable adjusted regression. 
The study population was primarily Caucasian (66%) or Asian (25%).  Most women were 
postmenopausal (64%) and normal weight (63%) at first mammogram.  In cross-sectional 
analysis, BMI was positively associated with DV (β=2.95 cm3, 95% CI 2.69, 3.21) and inversely 
associated with PDV (β=-2.03%, 95% CI -2.09, -1.98).  By contrast, in longitudinal analysis an 
annual increase in BMI was associated with an annual decrease in both DV (β=-1.01 cm3, 95% CI 
-1.59, -0.42) and PDV (β=-1.17%, 95% CI -1.31, -1.04).  These findings were consistent between 
pre- and postmenopausal women.  Among premenopausal women, the annual decrease in DV 
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was only observed among women who were initially overweight or obese (p<0.01 for interaction 
by initial BMI). 
Our findings support an inverse association between change in BMI and change in 
percent density.  Longitudinal studies of BMI or PDV and breast cancer risk should consider 
adjusting for change in the other factor.  The association between increasing BMI and decreasing 
absolute DV is unexpected and will require confirmation using SXA and other volumetric 
methods. 
1.2 Introduction 
Percent dense area (PDA), the ratio of dense breast tissue compared to total breast tissue 
on a mammographic image, is a known risk factor for primary breast cancer (1-4).  However, the 
relative contributions of dense and non-dense tissue to breast cancer risk are not fully understood.  
Dense tissue reflects epithelial and stromal tissue where malignant growth may initiate, and larger 
amounts may provide more opportunity for abnormal cell development (5).  Androstenedione is 
converted to estrogen in non-dense adipose tissue, and greater estrogen exposure also has been 
associated with increased risk (6).  In cross-sectional analysis, higher body mass index (BMI) has 
been strongly linked to higher non-dense area (NDA) and weakly linked to lower dense area 
(DA) on a mammographic image (2, 7, 8).  However, cross-sectional studies assessing dense 
breast volume have found positive associations between BMI and both non-dense volume (NDV) 
and dense volume (DV) (9-12).  Several methods of assessing breast volume have been proposed 
as enhancements over area assessment (11, 13-15).  Single X-ray absorptiometry (SXA), which 
calculates breast volume using a calibrated phantom included in the mammographic image, may 
more accurately predict breast cancer risk than area methods (15).  BMI and breast density may 
negatively confound each other in their associations with breast cancer risk (8, 16, 17).  
Understanding the impact of BMI on breast composition is necessary to determine how these 
factors should be included and controlled for in studies of risk. 
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Neither breast density nor BMI are static values.  It is understood that PDA decreases 
during aging, and that the rate of decline is greatest during the menopausal transition (18-20).  A 
recent study showed that PDA declined less over time for women who went on to be diagnosed 
with breast cancer than for age-matched controls (21).  It is unclear how changing BMI influences 
the decline in density.  A limited number of longitudinal studies have shown an inverse 
relationship between change in BMI and change in PDA (22, 23), and have reported either a null 
(22) or positive (23) association between change in BMI and change in absolute DA.  To date, no 
studies have evaluated the longitudinal effect of change in BMI on change in density using 
volumetric methods.  This relationship must be established to understand the impact of adjusting 
for unstable BMI in longitudinal studies that use change in breast density to reflect breast cancer 
risk. 
We examined the cross-sectional and longitudinal associations between BMI and breast 
density using the SXA volumetric density measurement method.  Our analysis was conducted in 
the Breast Cancer Surveillance Consortium, a large cohort of women undergoing breast imaging.  
Based on prior cross-sectional analyses using volumetric methods (9-12), we hypothesized that an 
increase in BMI over the study period would be associated with an increase in both dense volume 
(DV) and non-dense volume (NDV), and a decrease in percent dense volume (PDV). 
 
1.3 Methods 
1.3.1 Study population  
 The Breast Cancer Surveillance Consortium (BCSC) was established by the National 
Cancer Institute in 1994.  At each of seven locations, screening mammography data are linked to 
cancer registry information at each site then pooled across sites to provide a large sample of 
women.  The BCSC sites were selected to represent urban, suburban, and rural locations and a 
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diverse racial/ethnic pool.  As of February 2013, the full BCSC database included approximately 
9.5 million mammograms and over 113,000 breast cancer cases (24).   
The current study used data from the San Francisco Mammography Registry (SFMR), 
one of two BCSC sites at which volumetric mammographic density has been measured since 
2007.  At the time of their screening mammogram, women completed a self-administered, one-
page questionnaire providing basic demographic, medical, and reproductive history information.  
The questionnaire allowed women to opt out of having their data included in BCSC research.  
The average opt out rate for the facilities contributing to the SFMR is 1.8% (range: 0.8-3.3%).  
The eligible study sample included women age 18 and older with two or more mammograms in 
2007-2013 spaced at least nine months apart.  Women with history of breast cancer, mastectomy, 
breast implants, or breast surgery were excluded from the study sample.  Mammograms that were 
performed within 6 months of a breast cancer diagnosis were also excluded.  The eligible sample 
consisted of 30,000 women who contributed 75,489 mammograms.  A total of 1,149 
mammograms were excluded due to poor placement of the SXA phantom in the mammographic 
image resulting in volumetric density measurement error.  After this exclusion, 368 women had 
only one mammogram to contribute to the analysis and were therefore also excluded.  These 
exclusions resulted in an eligible study population of 29,632 women and 73,972 mammograms 
(average 2.54 mammograms per woman).  The average time between first and last contributed 
mammogram was 2.4 years (range 0.8-5.9 years). 
1.3.2 BMI assessment 
 Women self-reported their current height in inches and weight in pounds at the time of 
their screening mammogram, and these data were used to calculate BMI.  Women were excluded 
from the study sample if their reported height between mammograms varied by more than 3 
inches (470 women, 1,197 mammograms).  BMI was analyzed both in its original continuous 
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form and categorized according to WHO guidelines: <18.5 kg/m
2
 for underweight, 18.5-<25 
kg/m
2
 for normal weight, 25-<30 kg/m
2
 for overweight, and >=30 kg/m
2
 for obese.    
1.3.3 Volumetric breast density assessment 
 Dense breast volume and percent dense breast volume were measured using the single x-
ray absorptiometry (SXA) technique.  A complete description of the specific SXA imaging 
methods, development, and calibration processes can be found elsewhere (25, 26).  Briefly, a 
specialized SXA phantom was included in the x-ray field during the mammography examination 
and was used to convert pixel grayscale values into unique volumes of adipose (non-dense) and 
fibroglandular (dense) breast tissue for each given pixel value (26).  The SXA phantom was 
specifically designed to not interfere with standard screening procedures and to account for tilt of 
the compression surfaces during the examination (15, 26).  The mean difference in PDV 
measurements between repeat readings using this technique has been demonstrated to be less than 
2.5% (15).  
1.3.4 Covariate assessment 
 Data on demographics, reproductive and menstrual history, family history, and brief 
medical history were obtained via the one-page questionnaire administered at the time of the 
screening mammogram.  The covariates selected as potential confounders or effect modifiers for 
this analysis were based on known predictors of mammographic density and availability within 
the BCSC dataset.  Covariates assessed at the time of the first screening mammogram and 
considered unchanging included age at first mammogram, race, ever given birth, age at first birth, 
education, first degree family history of breast cancer, and prior history of breast biopsy.  Time-
varying covariates included menopausal status, hormone therapy use, and hormonal birth control 
use.  Consistent with previous analyses using BCSC data, women were considered 
postmenopausal if they reported that menstrual periods had stopped for more than 12 months, if 
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they reported a bilateral oophorectomy, or if they reported a hysterectomy and were 55 years of 
age or older.  Women were otherwise considered premenopausal.  Current use of hormone 
therapy and hormonal birth control were assessed at the time of the screening mammogram.  The 
questionnaire did not include specific formulations of hormone therapy or history of prior use. 
1.3.5 Statistical analysis 
We additionally excluded 4,606 women (11,122 mammograms) who were missing data 
on one or more covariates included in the multivariable model.  There were no statistically 
significant differences in the remaining covariates between women who were excluded from the 
analysis and those who were retained (data not shown).  The final analytic sample included 
24,556 women who contributed 61,653 mammograms.   
We calculated descriptive statistics for available demographic and reproductive 
characteristics.  We assessed the cross-sectional association between BMI at first mammogram 
and volumetric density measures at first mammogram using a generalized linear regression model 
adjusted for all covariates.  Log transformations of density variables were used to satisfy 
normality assumptions.  In longitudinal analyses we calculated annual change in BMI and 
volumetric density measures as (Δ value / Δ time, days) × 365.25 days/year to account for 
varying time lapse between mammograms.  We categorized BMI change over the study period 
based on change from initial BMI (at first mammogram): ≥10% loss, 5-10% loss, stable within 
±5%, 5-10% gain, and ≥10% gain.  We used ANOVA to compare the percent gain/loss based on 
initial BMI, using the underweight or normal range (<25 kg/m
2
) as the reference.  We 
summarized the annual change in each volumetric density measure over the study period and 
calculated adjusted means and confidence intervals using generalized linear regression. 
We assessed the association between annual change in BMI and annual change in DV, 
NDV, and PDV using a random intercept mixed effects model.  The mixed effects model is 
appropriate for data in which each subject may contribute a varying number of observations, and 
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the random intercept allows for individual subject variation in baseline density measures (27).  
The model was adjusted for all covariates listed above and time-varying factors were updated at 
each successive mammogram.  We stratified all analyses by menopausal status (premenopausal, 
postmenopausal, or transitioned from pre- to postmenopausal) because the association between 
BMI and breast cancer risk has been shown to vary between pre- and postmenopausal women 
(28, 29).  Because analyses have shown that declines in PDA over the menopausal transition may 
be modified by initial BMI and hormone therapy use (18, 19), we tested for effect modification 
by BMI at the first mammogram and by hormone therapy (never user, consistent user, initiated 
use during the study period, discontinued use during the study period). 
 All analyses were performed using SAS Version 9.2 (SAS Institute, Cary, North 
Carolina). 
1.4 Results 
 A majority of the study population was Caucasian (66.3%) with 25.1% Asian or Pacific 
Islander (Table 1).  The average age at the first mammogram was 56.4 years, and 64.1% of 
women were postmenopausal.  Over half of the study population was classified as normal weight 
at the first mammogram (62.6%), while 24.2% were classified as overweight and 10.9% were 
classified as obese.  About 12% of the study population was using hormone therapy at the time of 
the first mammogram. 
 In cross-sectional analysis, BMI at first mammogram was positively associated with both 
DV (β=2.95 cm3, 95% CI 2.69, 3.21) and NDV (β=51.03 cm3, 95% CI 49.93, 52.13) at first 
mammogram, and was inversely related to PDV at first mammogram (β=-2.03%, 95% CI -2.09, -
1.98) (Table 2).  The associations with NDV and with PDV were stronger among women who 
were initially premenopausal compared to those who were initially postmenopausal (p value for 
interaction by menopausal status: p=0.79 for DV, p<0.01 for NDV, p<0.01 for PDV).  No 
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significant interaction by hormone therapy (HT) use was observed (p value for interaction by HT 
use: p=0.60 for DV, p=0.15 for NDV, p=0.81 for PDV). 
A majority of women maintained stable weight within ± 5% of their initial BMI during 
the study period (73.6%) (Table 3).  Regardless of menopausal status, a higher proportion of 
women who were initally overweight or obese lost over 5% of their initial BMI compared to 
women who were initially lean (premenopausal: 6.1%, 16.4%, and 21.2% of normal, overweight, 
and obese women, respectively, p<0.01; postmenopausal: 9.3%, 18.3%, and 23.9% of normal, 
overweight, and obese women, respectively, p<0.01).  A higher proportion of initially overweight 
or obese premenopausal women gained over 5% of their initial BMI compared to initially lean 
premenopausal women (13.9%, 17.6%, and 17.0% of normal, overweight, and obese women, 
respectively, p = 0.01).  No difference in weight gain by initial BMI was observed among 
postmenopausal women (13.3%, 13.6%, 13.0% of normal, overweight, and obese women, 
respectively, p=0.86).   
The mean annual change in DV, NDV, and PDV over the study period was -0.56 
cm
3
/year, 6.09 cm
3
/year, and -0.81 %/year, respectively (data not shown).  A 1 kg/m
2
 annual 
increase in BMI was associated with a statistically significant decrease in DV (β=-1.01 cm3, 95% 
CI -1.59, -0.42), increase in NDV (β=26.2 cm3, 95% CI 23.5, 28.9), and decrease in PDV (β=-
1.17%, 95% CI -1.31, -1.04) in the full study population (Table 4).  Results were strongest among 
premenopausal women, although significant interaction by menopausal status was only observed 
for NDV and PDV (p value for interaction by menopausal status: p=0.43 for DV, p=0.01 for 
NDV, p<0.01 for PDV).  When further stratified by initial BMI, the significant annual decrease in 
DV was observed among premenopausal women who were intitally overweight or obese, but not 
among premenopausal women who were initially underweight or normal BMI (p value for 
interaction by initial BMI: p<0.01).  Among postmenopausal women, annual decrease in DV was 
not statistically significant after stratification by initial BMI and no interaction was observed (p 
value for interaction by initial BMI: p=0.67).  Likewise, no interaction between DV and initial 
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BMI was oberved among the women who transitioned from pre- to postmenopausal (p value for 
interaction by initial BMI: p=0.52).   Regardless of menopausal status, the significant annual 
decrease in PDV associated with an increase in BMI was strongest among initially lean women 
and progressively weaker among initially overweight and obese women (p value for interaction 
by intial BMI: p<0.01 for all menopausal status groups).  We observed no significant overall 
interaction by HT use (p value for interaction by HT use: p=0.44 for DV, p=0.15 for NDV, 
p=0.40 for PDV). 
1.5 Discussion 
 Consistent with our expectations, we observed positive cross-sectional relationships 
between BMI and both DV and NDV, and an inverse cross-sectional relationship between BMI 
and PDV.  We also observed that DV and PDV declined on average over the study period.  
However, in contrast to our expectations, we found that an annual increase in BMI was associated 
with an annual decrease in DV in longitudinal analysis.  This finding was consistent among pre- 
and postmenopausal women, and varied by initial BMI among premenopausal women.  An 
annual increase in BMI was further associated with an annual decrease in PDV among all 
menopausal status groups, as a result of increases in NDV associated with increasing BMI. 
Our finding of a positive cross-sectional relationship between BMI and DV is consistent 
with studies using the SXA method (12) and other volumetric techniques (9, 10, 30), but in 
contrast with studies using area assessment (8, 31).  Unlike area methods, which rely on a 
dichotomous separation of dense and non-dense area, the SXA method calculates a continuous 
value for DV based on the comparison of each pixel on the mammographic image to a known 
phantom (26).  Continuous assessment of DV may provide a more accurate assessment of dense 
tissue than dichotomous area methods.  Further, the SXA method includes water in adipose tissue 
in its calculation of DV (15).  A recent study comparing area and SXA volume measurements 
reported that correlations between DA and DV were stronger among lean women than among 
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obese women as a result of this inclusion (12).  The contribution of water from adipose tissue 
may partially account for the positive cross-sectional association between BMI and DV. 
Our observed 1.17% annual decline in PDV associated with a unit annual increase in 
BMI is similar in magnitude to the two previous studies of change in BMI and PDA over time, 
which reported annual declines of 0.36% (22) and 1.44% (23).  However, our observation of a 
decrease in DV with increasing BMI does not support their findings of no association (22) or 
positive association (23) between change in BMI and DA.  The association between change in 
BMI and change in DA observed by Reeves et al (22) was in the same direction as our finding, 
but their results among 833 women were not statistically significant.  Although we observed a 
significant annual decrease in DV, it should be noted that the magnitude, approximately 1 
cm
3
/year, is small compared to the initial average DV in our study population (142.3 cm
3
) and 
compared to the difference in DV that was associated with increased breast cancer risk in a case-
control analysis of 864 women using SXA (women in the highest quintiles of DV (192+ cm
3
) had 
significantly higher risk compared to those in the lowest quintile (<122.3 cm
3
)) (15).   
We observed that the longitudinal association between BMI and DV was strongest among 
premenopausal women who were initially overweight or obese.  These women were more likely 
to gain more than 5% of their initial weight during the study period than their lean counterparts.  
It is possible that the association between change in BMI and DV was easiest to observe among 
women who gained more weight, since a larger change in BMI may allow us to see the associated 
small change in DV.  The inverse association between BMI and DV also was observed among 
postmenopausal women, but did not vary by initial BMI.  Likewise, no difference in weight gain 
by initial BMI was observed among postmenopausal women who were postmenopausal at 
baseline.  The biological mechanism linking an annual increase in BMI to an annual decrease in 
absolute DV is unclear.  Like other volumetric methods, the SXA technique calculates breast 
volume based on the two-dimensional mammographic image.  It is possible that our finding may 
reflect differences in capturing dense breast tissue on a mammographic image for large- versus 
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small-breasted women as opposed to a true reduction in DV with increasing BMI.  Future studies 
using SXA and other volumetric measurement techniques are necessary to confirm our results.  
Joint cross-sectional analyses of BMI and PDA and breast cancer risk suggest that these 
are independent breast cancer risk factors in both pre- and postmenopausal women (8, 17, 32), 
and that the association of either factor with breast cancer risk is strengthened after adjustment for 
the other factor (8, 32).  Therefore studies of either factor should control for the other to avoid 
negative confounding.  The significant associations that we observed between change in BMI and 
change in density measures suggest that longitudinal studies of volumetric density and breast 
cancer risk should additionally consider adjusting for change in BMI (i.e. weight gain or loss) to 
fully understand the independent effect of change in volumetric density on breast cancer risk.  
Further, longitudinal studies using change in density outcomes as an indicator of changing breast 
cancer risk should carefully evaluate the potential for confouding by gain or loss in BMI and also 
consider adjustment as necessary. 
 Our study is strengthened by the large number of participants and by the fact that height 
and weight were reported at the time of the screening mammogram.  In addition, volumetric 
density was assessed using a validated method that has been found to more accurately predict 
breast cancer risk than area assessment (15).  Our results must be interpreted in context of the 
study limitations, however.  First, height and weight were self-reported.  Validity of self-reported 
height and weight measures has been assessed within a subset of the BCSC cohort (12) and the 
Spearman correlation coefficient between BMI from self-reported and measured values was 0.949 
(95% CI 0.938, 0.957).  Second, our ability to adjust for confounding variables is limited by the 
information collected on the BCSC questionnaire.  The questionnaire was designed to minimize 
burden on women at their routine screening mammogram and therefore includes fewer questions 
than might be asked during a targeted research study.  We have adjusted for confounding to the 
extent possible, but residual confounding by other factors related to BMI and breast density may 
exist.  Lastly, our study sample was primarily Caucasian and Asian women.  Both 
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mammographic density (33, 34) and body composition (28) have been shown to vary by 
racial/ethnic group, meaning that our findings may not be generalizable to a more diverse 
population. 
 The independent and collective roles of BMI and breast density in breast carcinogenesis 
are unclear and are complicated by the dynamic nature of both body and breast composition over 
time.  This analysis supports the current understanding that an increase in BMI is associated with 
a decrease in percent density and suggests that change in PDV over time may differ based on 
starting BMI.  Our unexpected finding of a decrease in DV with increasing BMI is contrary to our 
current understanding of the mechanisms relating dense breast tissue, BMI, and breast cancer 
risk.  Confirmation using other volumetric techniques is required to ensure that our finding is not 
the result of chance or an artifact of our measurement method.  
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Table 1: Selected patient characteristics measured at first mammogram 
(N=24,556); BCSC SFMR 2007-2013 
 
 
 
Study population
N (%)
General characteristics
Age at mammogram (years); Mean (SD) 56.4 (10.9)
BMI (kg/m
2
); Mean (SD) 24.5 (4.6)
Underweight: <18.5 583 (2.4)
Normal weight: 18.5 - <25 15,363 (62.6)
Overweight: 25 - <30 5,938 (24.2)
Obese: 30+ 2,672 (10.9)
Race
Caucasian 16,268 (66.3)
African-American 519 (2.1)
Asian / Pacific Islander 6,184 (25.2)
Other 1,585 (6.4)
Education level
< High school 747 (3.0)
High school diploma 1,820 (7.4)
Some college 4,970 (20.2)
College degree 17,019 (69.3)
First degree family history of breast cancer 4,787 (19.5)
Previous breast biopsy 5,785 (23.6)
Reproductive history
Menopausal status
Premenopausal 8,355 (34.0)
Postmenopausal 15,734 (64.1)
Ever given birth 16,315 (66.4)
Age at first birth
Nulliparous 8,183 (33.3)
< 20 years 835 (3.4)
20 - 29 years 7,681 (31.3)
30 - 39 years 7,031 (28.6)
40+ years 826 (3.4)
Hormone therapy use (at first mammogram) 3,001 (12.2)
Birth control hormone use (at first mammogram) 1,493 (6.1)
Tamoxifen or raloxifene use (at first mammogram) 204 (< 1.0)
Percentages may not add to 100% due to unknown values (<10% for any 
characteristic)
  
Table 2: Cross-sectional association between BMI and volumetric density measures at first mammogram; BCSC SFMR 
2007-2013 
 
 
 
 
N
(women)
Mean (SD) at first 
mammogram β (SE)
 a
95% CI P value
All women 24,556
Dense breast volume (cm
3
) 142.3 (76.7) 2.95 (0.13) 2.69, 3.21 <0.001
Non-dense breast volume (cm
3
) 416.8 (331.0) 51.03 (0.56) 49.93, 52.13 <0.001
Percent dense breast volume (%) 32.5 (19.5) -2.03 (0.03) -2.09, -1.98 <0.001
Premenopausal at first mammogram 8,355
Dense breast volume (cm
3
) 166.7 (83.7) 3.05 (0.27) 2.51, 3.58 < 0.001
Non-dense breast volume (cm
3
) 327.1 (303.2) 53.64 (0.98) 51.72, 55.55 < 0.001
Percent dense breast volume (%) 42.3 (21.3) -2.88 (0.06) -3.00, -2.77 < 0.001
Postmenopausal at first mammogram 15,734
Dense breast volume (cm
3
) 129.1 (69.1) 2.97 (0.16) 2.67, 3.28 < 0.001
Non-dense breast volume (cm
3
) 465.6 (336.2) 49.96 (0.69) 48.61, 51.31 < 0.001
Percent dense breast volume (%) 27.3 (16.2) -1.67 (0.03) -1.73, -1.61 < 0.001
a
 Adjusted for age at first mammogram, race, education, first degree family history of breast cancer, history of breast biopsy, 
ever given birth (yes/no), menopausal status at first mammogram (all women), and hormone use at first mammogram
Stratified results exclude 467 women with unknown menopausal status at first mammogram
  
Table 3: Change in BMI from first mammogram to last mammogram, stratified by menopausal status and by BMI at first mammogram 
(kg/m
2
); BCSC SFMR 2007-2013 
 
 
 
 
N
(women)
> 10% loss
N (%)
5-10% loss
N (%)
Stable ± 5%
N (%)
5-10% gain
N (%)
> 10% gain
N (%)
All women 24,556 839 (3.4) 2,177 (8.9) 18,059 (73.6) 2,584 (10.5) 897 (3.6)
Premenopausal (all exams) 7,266
Underweight or normal: <25 5,203 45 (0.9) 271 (5.2) 4,163 (80.0) 558 (10.7) 166 (3.2)
Overweight: 25 - <30 1,487 71 (4.8) 172 (11.6) 983 (66.0) 185 (12.4) 78 (5.2)
Obese: 30+ 576 57 (9.9) 65 (11.3) 356 (61.8) 78 (13.5) 20 (3.5)
Postmenopausal (all exams) 15,715
Underweight or normal: <25 9,682 168 (1.7) 735 (7.6) 7,489 (77.4) 956 (9.9) 331 (3.4)
Overweight: 25 - <30 4,093 239 (5.8) 513 (12.5) 2,787 (68.1) 417 (10.2) 137 (3.4)
Obese: 30+ 1,940 191 (9.9) 272 (14.0) 1,224 (63.1) 181 (9.3) 72 (3.7)
Transition from pre- to postmenopausal 1,089
Underweight or normal: <25 728 14 (1.9) 57 (7.8) 519 (71.3) 100 (13.7) 38 (5.2)
Overweight: 25 - <30 260 17 (6.5) 27 (10.4) 166 (63.9) 33 (12.7) 17 (6.5)
Obese: 30+ 101 12 (11.9) 14 (13.9) 59 (58.4) 9 (8.9) 7 (6.9)
Stratified results exclude observations for 486 women with unknown menopausal status at one or more mammogram(s)
  
Table 4: Association between annual change in BMI and annual change in volumetric density measures, stratified by menopausal status 
and by BMI at first mammogram (kg/m
2
); BCSC SFMR 2007-2013 
 
 
 
 
 
N
(women) β (SE)
 a 95% CI p value β (SE)
 a 95% CI p value β (SE)
 a 95% CI p value
All women 24,556 -1.01 (0.30) -1.59, -0.42 0.001 26.2 (1.38) 23.45, 28.87 < 0.001 -1.17 (0.07) -1.31, -1.04 < 0.001
Premenopausal (all exams) 7,266 -1.73 (0.73) -3.17, -0.30 0.02 32.64 (2.63) 27.47, 37.80 < 0.001 -1.83 (0.14) -2.10, -1.56 < 0.001
Underweight or normal: <25 5,203 0.92 (0.74) -0.52, 2.37 0.21 31.17 (2.65) 25.97, 36.37 < 0.001 -2.84 (0.23) -3.30, -2.38 < 0.001
Overweight: 25 - <30 1,487 -2.71 (0.98) -4.63, -0.80 0.01 33.56 (4.50) 24.74, 42.37 < 0.001 -1.47 (0.21) -1.87, -1.07 < 0.001
Obese: 30+ 576 -3.29 (1.90) -7.01, 0.44 0.08 32.63 (6.48) 19.93, 45.32 < 0.001 -0.86 (0.17) -1.18, -0.53 < 0.001
Postmenopausal (all exams) 15,715 -0.74 (0.32) -1.36, -0.12 0.02 24.08 (1.63) 20.89, 27.27 < 0.001 -0.95 (0.08) -1.10, -0.80 < 0.001
Underweight or normal: <25 9,682 -0.32 (0.32) -0.95, 0.31 0.32 22.93 (2.95) 17.15, 28.70 < 0.001 -1.51 (0.20) -1.91, -1.11 < 0.001
Overweight: 25 - <30 4,093 -0.94 (0.66) -2.23, 0.36 0.16 31.09 (1.73) 27.70, 34.47 < 0.001 -1.08 (0.11) -1.29, -0.87 < 0.001
Obese: 30+ 1,940 -0.53 (0.61) -1.73, 0.67 0.39 20.57 (2.56) 15.55, 25.58 < 0.001 -0.35 (0.09) -0.52, -0.17 < 0.001
Transition from pre- to postmenopausal 1,089 -1.40 (1.85) -5.02, 2.23 0.45 24.20 (5.15) 14.11, 34.29 < 0.001 -1.48 (0.27) -2.02, -0.94 < 0.001
Underweight or normal: <25 728 -0.62 (1.22) -3.02, 1.78 0.61 33.24 (4.76) 23.91, 42.58 < 0.001 -2.89 (0.43) -3.73, -2.05 < 0.001
Overweight: 25 - <30 260 -2.81 (1.30) -5.36, -0.27 0.03 22.80 (9.92) 3.35, 42.25 0.02 -1.25 (0.49) -2.21, -0.29 0.01
Obese: 30+ 101 0.21 (4.70) -9.00, 9.43 0.96 17.94 (8.42) 1.44, 34.44 0.03 -0.35 (0.33) -0.99, 0.29 0.28
postmenopausal women: DV p=0.67, NDV p<0.01, PDV p<0.01
transitioning women: DV p=0.52, NDV p=0.24, PDV p<0.01
Stratified results exclude observations for 486 women with unknown menopausal status at one or more mammogram(s)
P value for interaction by menopausal status: DV p=0.43, NDV p=0.01, PDV p<0.01
Annual change in dense breast volume
(cm
3
 per year)
Annual change in non-dense breast volume
(cm
3
 per year)
Annual change in percent dense breast volume
(% per year)
a
 Adjusted for age at first mammogram, age at first birth, history of breast biopsy, education, ever given birth (yes/no), first degree family history of breast cancer, hormone use during study period, menopausal 
status (all women), and race
P value for interaction by BMI at first mammogram: premenopausal women: DV p<0.01, NDV p=0.87, PDV p<0.01
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CHAPTER 2 
 
MENOPAUSAL VASOMOTOR SYMPTOMS AND MAMMOGRAPHIC DENSITY IN 
THE STUDY OF WOMEN’S HEALTH ACROSS THE NATION 
2.1 Abstract 
Declines in endogenous estrogen during menopause have been independently linked to 
the onset of menopausal vasomotor symptoms (VMS) and to reduced breast cancer risk.  Percent 
mammographic density (PMD) is viewed as a marker for breast cancer susceptibility.  A 
relationship between VMS and PMD may improve understanding of breast cancer etiology and 
justify future investigations of VMS and breast cancer risk.   
We investigated this association among 833 women enrolled in the Study of Women’s 
Health Across the Nation (SWAN) Mammgraphic Density Substudy.  Women were pre- or 
perimenopausal at enrollment and followed for six annual visits.  VMS were self-reported at 
annual SWAN visits.  PMD was ascertained from routine screening mammograms.  A linear 
mixed effects model was used to evaluate the longitudinal association between VMS and PMD.   
Women contributed a total of 4,748 mammograms (2-10 per woman) over a median 5.4 
years of follow-up.   We observed no overall association between VMS and PMD.  Among 
perimenopausal women, VMS was associated with significantly lower PMD (β = -1.29%, 95% CI 
-2.58, -0.001).  Similar results were observed among those with unknown menopausal status due 
to hormone use during follow-up (β = -3.62%, 95% CI -7.17, -0.07).  Among women who 
transitioned to postmenopause without surgery, VMS was not associated with change in PMD 
across the menopausal transition.  
Although our findings do not demonstrate a consistent relationship between VMS and 
PMD, we did observe an association among perimenopausal women and those using hormone 
therapy during the menopausal transition.  Further prospective studies are needed to determine the 
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extent to which an observed decrease in breast cancer risk among women with VMS may be 
mediated by PMD.  
2.2 Introduction 
Menopausal vasomotor symptoms (VMS), which include hot flashes and night sweats, 
are frequently reported by women during menopause, occurring in up to 75% of women during 
and after the menopausal transition (35-38). Two recent case-control studies (39, 40) and one 
prospective study (Hart, in preparation) observed a 40-50% reduction in breast cancer risk among 
women who experienced VMS at any point during the menopausal transition compared to those 
who did not.     
The mechanism that triggers the onset of VMS in symptomatic women may be related to 
a mechanism responsible for lower breast cancer susceptibility.  Higher levels of endogenous 
estrogens have been positively associated with postmenopausal breast cancer risk (41); whereas 
the fluctuation and eventual decline in estrogen levels prior to menopause appears to be related to 
VMS onset.  Previous work demonstrates that estrogen fluctuations may be responsible for a 
narrowing of the thermoneutral range (42), for a lack of responsiveness to thermal changes at the 
skin vasculature (43), and for changes in the regulation of central nervous system chemicals that 
trigger thermoregulatory response (44, 45).  Hormone therapy (HT) has been shown to be a 
consistently effective treatment for VMS (46), indicating that the regulation of estrogen levels is 
important to the management of symptoms.  However, non-hormonal treatments also have been 
shown to relieve VMS (47, 48), suggesting that VMS may be triggered by factors other than 
fluctuating hormone levels. 
Percent mammographic density (PMD), the proportion of dense epithelial and connective 
breast tissue compared to total breast tissue on a mammographic image (2), has been consistently 
demonstrated as a strong risk factor for breast cancer (49), and high PMD is viewed as a marker 
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of breast cancer susceptibility (50).  The role of menopausal hormone fluctuations on PMD is 
unclear, although studies have shown consistent declines in PMD and dense breast area with age 
and across the menopausal transition (18, 19, 51).  Investigations also have found positive 
associations between PMD and circulating estradiol (52, 53).  Declines in PMD during 
menopause appear to be modified by HT use, further suggesting hormonal influences on changes 
in breast tissue (18, 19).  Common  hormonal mechanisms affecting VMS and PMD provide 
justification for examining the relationship between these factors, and have the potential to 
provide prospective information regarding VMS and future breast cancer risk among healthy 
women. 
We evaluated the association of VMS with PMD in the Study of Women’s Health Across 
the Nation (SWAN), a large prospective cohort of women transitioning through menopause.  We 
anticipated that VMS would be associated with lower PMD and indicative of a lower 
susceptibility to breast cancer.  Specifically, we hypothesized that VMS would be inversely 
associated with PMD, overall and within each menopausal stage.  We additionally hypothesized 
that women who experienced VMS while pre- or perimenopausal would have a greater decline in 
PMD across the menopausal transition compared to women who did not experience VMS while 
pre- or perimenopausal. 
2.3 Methods 
2.3.1 Study population 
The Study of Women’s Health Across the Nation (SWAN) was designed to characterize 
biological and psychosocial changes over the menopausal transition in a multiracial/ethnic cohort.  
A detailed description of the SWAN design and recruitment procedures is provided elsewhere 
(54).  Briefly, each of seven SWAN sites recruited women starting in 1996, with certain locations 
oversampling from specific racial/ethnic groups to create a diverse cohort.  Baseline eligibility 
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criteria for SWAN enrollment included being aged 42-52 years, having an intact uterus and at 
least one ovary, not being pregnant or lactating, not using oral contraceptives or hormone therapy, 
and having a menstrual cycle in the three months before enrollment.  A total of 3,302 women 
were enrolled, and each participant provided written informed consent at the location of 
enrollment.  Baseline clinical assessments were performed in 1996-1997 and annual follow-up 
assessments are on-going. 
The current study involved SWAN participants enrolled in the ancillary Mammographic 
Density Sub-study.  This sub-study was designed to examine factors related to mammographic 
density and changes in mammographic density over the course of the menopausal transition.  
Women at three SWAN sites were enrolled in the sub-study during follow-up visit 05 or 06 
(N=1,055), representing four racial/ethnic groups.  African-American women were enrolled from 
the Pittsburgh, PA site, Chinese women from the Oakland, CA site, and Japanese women from 
the Los Angeles, CA site.  Caucasian women were enrolled from all three locations.  Separate 
written informed consent was obtained from these women to obtain prior mammograms taken at 
routine screenings up to two years prior to the baseline SWAN visit through two years after 
follow-up visit 06.  Women with a previous breast surgery in both breasts (i.e., breast 
augmentation, reduction or reconstruction) were not eligible for the Mammographic Density Sub-
study.  At least one mammogram was obtained from 95.5% of the eligible sub-study sample 
(N=1,007). 
The current study excluded six women with a history of breast cancer at SWAN 
enrollment.  A further 21 women were diagnosed with breast cancer during the follow-up period 
and were censored at the time of their diagnosis; however, ten of these women had no 
mammograms available prior to diagnosis and were therefore excluded completely.  The outcome 
of the current study was change in PMD across the menopausal transition; therefore, the 139 
women with only one eligible mammogram were excluded, leaving 852 participants in the study 
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population.  Three women reported being pregnant or breastfeeding during the follow-up period, 
and information from these specific visits also was excluded. 
2.3.2 Vasomotor symptom assessment 
At the baseline and each follow-up visit, SWAN participants completed a self-
administered questionnaire that included questions related to hot flashes and night sweats.  The 
questions were worded as follows: “Thinking back over the last two weeks, how often have you 
had hot flashes or flushes / night sweats?”  Response categories were: not at all, 1-5 days, 6-8 
days, 9-13 days, every day.  Consistent with previous analyses in the SWAN cohort (55-57), 
women who reported any hot flashes or night sweats (versus not at all) were classified as having 
VMS at that visit.  Women who reported having hot flashes or night sweats on 6 or more days in 
the last two weeks were classified as having frequent VMS at that visit (38), while women who 
reported having hot flashes or night sweats 1-5 days in the last two weeks were classified as 
having infrequent VMS at that visit. 
2.3.3 Mammographic density assessment 
 Mammographic density assessments for the obtained mammograms were performed by a 
single expert reader using a compensating polar planimeter (LASICO, Los Angeles, CA) to 
measure total breast area and dense breast area in cm
2
 on the craniocaudal view of the right 
breast.  Mammograms from the left breast were used for density assessment when a woman 
reported biopsy or other surgery in the right breast or when films from the right breast were 
unavailable.  Percent density was calculated by dividing the area of dense breast tissue by the 
total area of the breast.  A blinded random sample of mammogram films was sent to the reader 
for re-review to assess the reproducibility of the density assessments.  The initial and repeat 
readings resulted in a within-person Spearman correlation coefficient of 0.96 and a mean 
difference in percent density assessment of 2.2% (22, 58). 
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Because mammograms were retrospectively collected from routine screening visits, 
mammogram dates did not typically coincide with SWAN visit dates.  As a result, a difference of 
several months may have existed between the collection of VMS and covariate information and 
mammographic density assessment.  We addressed this issue by matching each mammogram date 
to the closest SWAN visit date (before or after the mammogram) for mammograms that occurred 
within 90 days of a SWAN visit date (48.6% of eligible mammograms).  For the remaining 
mammograms, we used a novel interpolation method to estimate mammographic density at the 
time of the SWAN visit dates using linear interpolation with multiple imputation to account for 
error in the estimation.  This method was developed by Reeves et al for the study of changes in 
anthropometry with respect to mammographic density in SWAN and may provide more accurate 
estimations of mammographic density at the time of the SWAN visit by accounting for the lack of 
concordance between the timing of the mammogram and the timing of the SWAN visit.  Details 
and validation of this method are provided elsewhere (22, 59). 
2.3.4 Covariate assessment 
 Information on covariates was collected during annual SWAN follow-up visits as part of 
the clinical assessment or by interviewer- or self-administered questionnaires.  The covariates 
selected as potential confounders or effect modifiers for this analysis were consistent with 
previous investigations of mammographic density in the SWAN cohort (22, 58, 60, 61).  The 
following covariates were measured at baseline and considered unchanging: race/ethnicity, age at 
first birth, age at menarche, education, alcohol intake, smoking, and SWAN site.  The following 
additional covariates were considered time-varying and updated at each follow-up visit: 
menopausal status, body mass index (BMI), parity, family history of breast cancer, hormone 
therapy (HT) use, and oral contraceptive (OC) use.  We considered both active and passive 
exposure to smoking in our analysis, because previous investigations in the SWAN cohort have 
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observed differences in these exposures with respect to both VMS and PMD (38, 62).  Consistent 
with the analysis of smoking and PMD by Butler et al (62), we categorized our smoking variable 
as: never smoked/no passive exposure, never smoked/with passive exposure, former smoker, 
current smoker.   
 Prior HT use was assessed during the baseline interview.  By study design, women were 
not currently using HT at study enrollment but could initiate HT use during follow-up.  Past year 
HT use was assessed at each annual follow-up interview.  Women were asked to separately report 
the use of estrogen, progestin, and estrogen/progestin combination therapies and formulations 
were confirmed when possible using container labels.  Menopausal status was classified in 
accordance with SWAN protocol (54): women with no change in menstrual regularity over the 
past year were considered premenopausal; women with decreased menstrual regularity in the past 
three months were considered early perimenopausal; women with no menstrual bleeding in the 3-
11 months before the interview date were considered late perimenopausal; and those with no 
bleeding in the last 12 months were considered postmenopausal.  Early and late perimenopause 
were collapsed into a single perimenopause category for this analysis.  Women who reported 
bleeding in the previous 12 months and reported HT use in the previous year were reclassified as 
unknown menopausal status due to HT use for those visits.  Postmenopausal women remained 
classified as such, regardless of HT use initiated after the final menstrual period.  Women 
reporting a hysterectomy or bilateral oophorectomy were classified as surgically postmenopausal 
starting at the visit at which the surgery was reported. 
2.3.5 Statistical methods 
 After applying the matching and interpolation methods described above, 19 women no 
longer had two eligible mammograms matched to SWAN visits and were therefore excluded from 
the study, leaving a total of 833 women.  We calculated descriptive statistics for demographic and 
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reproductive characteristics of the study sample and summarized VMS experience in the 
population during the study period overall and by menopausal status. 
Association of VMS with PMD:  We used a linear mixed effects model to assess the 
longitudinal association between VMS and PMD across the study period while accommodating 
varying numbers of observations per woman and within-woman correlation.  We included a 
random intercept term to account for differing baseline PMD values.  We evaluated a random 
slope term to account additionally for differing changes in PMD over the study period; however, 
this term did not significantly enhance the model fit, so we performed the analysis using the 
simpler model.  The multivariable model was developed using methods of best selection.  We 
assessed the univariable associations between each covariate and the exposure and outcome to 
identify potential confounders.  Confounders were retained in the multivariable model if they 
were statistically significant (p<0.05) in the model or if their removal resulted in a change in the 
regression coefficient for the VMS exposure of 10% or more.   
To differentiate between symptomatic and non-symptomatic women, we modeled VMS 
at each study visit as VMS reported at that visit or any prior visit.  Therefore, a woman reporting 
VMS at a study visit was considered symptomatic from that visit forward.  This strategy was 
replicated for frequent VMS (i.e., a woman reporting frequent VMS at a study visit was 
considered symptomatic of frequent VMS from that visit forward).  HT use was modeled 
similarly to comprehensively capture use of exogenous hormones during the study period.  
Because BMI is strongly associated with both VMS (38) and PMD (33), we created separate 
models with and without adjustment for BMI.  We assessed interactions with VMS by 
race/ethnicity, HT use, and menopausal status using cross-product terms and where statistically 
significant interactions were observed, we stratified the results by levels of the interaction 
variable.  Because hysterectomy and/or bilateral oophorectomy may be related to VMS (37), we 
repeated our analyses in the subset of women who had not undergone either of these procedures.   
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VMS and change in PMD:  To assess the change in PMD over study period, we created 
an outcome variable to represent the difference between the earliest and latest PMD observation 
for each woman and an additional variable to quantify the time difference between these 
observations.  We used linear regression to determine adjusted mean change in PMD over the 
study period and to test for differences by VMS experience, adjusting for the time difference in 
our analysis.  This analysis was restricted to women who non-surgically transitioned from pre- or 
early perimenopausal to postmenopausal during the study period (N=426). 
 All analyses were performed using SAS Version 9.2 (SAS Institute, Cary, North 
Carolina). 
2.4 Results 
The 833 women included in the study population contributed a total of 4,748 
mammograms (median 4, range 2-10 mammograms per woman).  The average time between 
mammograms was a median of 469 days (interquartile range 385-728 days).  On average, women 
were 47 years old at SWAN enrollment and were premenopausal (58%) (Table 5).  A majority of 
the study population was Caucasian (49%) or Asian (44%), and most reported having a college 
education (54%).  Overall, 51% of women reported any VMS during at least one SWAN study 
visit.  This varied by menopausal stage, with 28%, 58% and 46% of women reporting having ever 
experienced symptoms while pre-, peri-, or postmenopausal, respectively. 
Association of VMS with PMD:  In the full study sample, no significant difference in 
PMD was observed between symptomatic and non-symptomatic women after adjustment for 
covariates including BMI (β = -0.47%, 95% CI -1.39, 0.45) (Table 6).  Among women who 
reported HT use during the study period, results suggested an inverse relationship between VMS 
and PMD (β = -3.02%, 95% CI -5.59, -0.52), although this association was attenuated and not 
statistically significant after adjustment for BMI (β = -2.31%, 95% CI -4.83, 0.21) (Table 6). 
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No interaction was observed between VMS and race/ethnicity (p=0.19); however, a 
significant interaction was observed by menopausal status (p<0.01).  During perimenopausal 
visits, symptomatic women had significantly lower PMD than non-symptomatic perimenopausal 
women, even following adjustment for BMI (β = -1.29%, 95% CI -2.58, -0.001) (Figure 1).  This 
finding was stronger among women who experienced frequent VMS, although the confidence 
interval was wider and non-significant (β = -2.13%, 95% CI -4.39, 0.24).  A similar, significant 
relationship was observed among women with unknown menopausal status due to HT use (β = -
3.62%, 95% CI -7.17, -0.07) and was again strongest in women who were symptomatic of 
frequent VMS (β = -6.07%, 95% CI -11.4, -0.77).  When grouped by type of HT use, the 
relationship was evident among women of unknown menopausal status using progestin or 
estrogen/progestin combination HT (β = -4.61%, 95% CI -8.38, -0.84), but not among similar 
women using estrogen only HT (β = 3.09%, 95% CI -9.23, -15.4) (Figure 1).  Results were 
similar when the 54 women who reported a hysterectomy and/or bilateral oophorectomy during 
the study period were excluded from the analyses (data not shown). 
VMS and change in PMD:  A total of 426 women fully transitioned from pre- or 
perimenopause to postmenopause during the study period without a surgically induced 
menopause.  Compared to women who did not transition to postmenopause during the study 
period, these women were slightly older (average age at enrollment 47.7 years compared to 45.2 
years), reported fewer perimenopausal visits (average 3.4 visits compared to 4.9 visits), were 
more likely to report VMS during perimenopausal visits (50.4% of visits compared to 45.8% of 
visits), and were more likely to use HT during the study period (48% compared to 39%).  
Average age at menopause for these women was 52.7 years. 
Although not statistically significant, symptomatic women had slightly higher starting 
and ending PMD than non-symptomatic women (starting PMD: average 43.5% compared to 
42.0%; ending PMD: average 37.3% compared to 35.7%) (Table 7).  No significant difference 
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was observed between symptomatic and non-symptomatic women in the change in PMD across 
the menopausal transition.  The adjusted mean decrease in PMD was 5.3% for symptomatic 
women compared to an adjusted mean decrease of 5.4% for non-symptomatic women (p=0.97) 
(Table 7). 
2.5 Discussion 
 In this racially/ethnically diverse prospective cohort, we observed no association between 
VMS and PMD in the overall study population or among premenopausal or postmenopausal 
women.  Lower PMD was observed among women who were symptomatic for VMS in both the 
perimenopausal group and the group with unknown menopausal status due to HT use, which 
likely includes primarily women who are truly perimenopausal.  Among women who transitioned 
to postmenopause without surgery during the study period, we observed no significant difference 
in the decline in PMD over the menopausal transition for symptomatic compared to non-
symptomatic women. 
 Two case-control studies reported significantly lower breast cancer risk among women 
who experienced VMS during the menopausal transition compared to those who did not (39, 40).  
However, results from prospective studies have been mixed.  No association was observed in a 
large prospective cohort with 13.7 years of follow-up and VMS assessment at three year intervals 
(63), but a significant 38% reduction in breast cancer risk was observed in a prospective 
investigation within the full SWAN cohort with 11.4 years of follow-up and annual VMS 
assessment (Hart, in preparation).  The mechanisms linking VMS to breast cancer risk are not 
well understood, and PMD may offer one pathway through which this association may be 
observed.  However, the biological connection between VMS and PMD, and ultimately breast 
cancer risk, is complex and may be influenced by numerous factors.  Fluctuating estrogen levels 
during menopause may disrupt the thermoregulatory system that triggers VMS (42).  However, 
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all women experience estrogen decline during menopause but not all women experience VMS, 
indicating that estrogen withdrawal alone cannot account for VMS onset.  Significant associations 
have been observed between PMD and circulating estradiol (52, 53), but these findings are 
inconsistent (64-67); and two investigations of the combined effects of circulating estradiol and 
PMD concluded that hormone levels and PMD are independent risk factors for breast cancer and 
only weakly related to each other (68, 69).  These associations are further complicated by HT use 
and BMI, which are each independently associated with VMS (38, 46), PMD (33, 70-72), and 
breast cancer risk (6, 41, 73).  We have carefullly adjusted for these factors in our analyses, and 
our overall null results suggest that the previously reported breast cancer risk reduction among 
women symptomatic for VMS is not likely mediated through observable effects of these factors 
on PMD.  
Although we did not observe an overall relationship between VMS and PMD, an 
association was found among perimenopausal women, when VMS are typically the most 
prevalent (35, 74), and among women with unknown menopausal status due to HT use, which is 
often prescribed for the management of menopausal symptoms (46).  Thus our findings suggest 
that VMS may be associated with PMD while women are experiencing the most frequent or 
intense VMS.  Use of progestin or estrogen/progestin combination HT has been shown to be 
associated with higher PMD (70-72).  The significant association between VMS and lower PMD 
among women using HT, and particularly progestin or combination HT (Figure 1), may be 
observable because higher initial PMD makes it easier to witness a reduction in PMD; however, 
future investigation would be required to substantiate this hypothesis.  The magnitude of the 
change in PMD associated with VMS in our study (4.6%) is similar to the decrease in PMD for 
parous versus nonparous women (approximately 2% per pregnancy (75)), but smaller than the 
typical decline in PMD for all women over the menopausal transition (mean 7.7%, 95% CI 1.9-
14.4% (18)).  Significant associations were not observed among postmenopausal women in our 
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study, regardless of HT use (Figure 1).  These results may be partially explained by a lack of 
statistical power in these subgroups or by our definition of VMS, which classified a woman as 
symptomatic from the point at which VMS were first reported. If the effect of VMS on PMD was 
only evident during the time at which VMS were experienced, this definition of VMS could have 
contributed to the observed attenuation of results among postmenopausal women. 
To our knowledge, no previous study has investigated the change in PMD in women 
undergoing the menopausal transition in relation to their VMS experience.  Consistent with 
previous investigations (18, 19, 76), PMD declined on average over follow-up for our study 
sample; however, we observed no difference in the change in PMD for symptomatic versus non-
symptomatic women.  Our findings of significantly lower PMD among symptomatic women 
during perimenopause, when VMS may be most frequent or intense, suggest that differences in 
the rate of change in PMD may be restricted to the perimenopause phase of the menopausal 
transition.  However, secondary analysis of the change in PMD across only perimenopausal visits 
did not show evidence of a difference by VMS experience (data not shown).  These results 
support our assertion that the observed associations between VMS and breast cancer risk may act 
through a mechanism that is not strongly related to PMD. 
Strengths of this study include the large, population-based cohort.  In addition, 
menopausal status and hormone therapy use were carefully defined and monitored in SWAN, 
allowing us to stratify and examine associations within specific subgroups.  Further, 
mammographic density was assessed by a single expert reader with high reliability.  Our study 
also includes some limitations.  First, the mammograms used for PMD assessment were not taken 
at the time of the annual SWAN visits at which VMS were assessed.  Although considerable 
effort was made to minimize the effect of this time difference via matching and interpolation, 
some inaccuracy may have been introduced into our analysis.  This inaccuracy was unlikely to be 
differential by VMS experience, meaning that our results would be attenuated and less significant 
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than we would have otherwise observed.  Second, VMS experience was assessed at each annual 
SWAN visit, at which participants were asked to report their VMS experience over the past two 
weeks.  Because the menopausal transition is a period of dynamic changes and symptoms may 
vary over the course of a year, this assessment may have failed to completely capture VMS.  In 
addition, our description of VMS frequency based on number of symptomatic days in the past 
two weeks does not capture VMS severity, which may vary based on intensity and number of 
episodes per day.  However, our VMS assessment was more comprehensive than that performed 
in the previous longitudinal evaluation of VMS and incident breast cancer risk.  Previous analysis 
has shown that self-report of VMS differs significantly by racial/ethnic group (77, 78), and Asian 
women in particular are less likely to report VMS than Caucasian or African American women 
(79).  Our study sample was approximately 44% Asian.  Although we observed no evidence of an 
interaction by race/ethnicity, our findings may not be generalizable to populations of women with 
a considerably different racial/ethnic mix.  Finally, because of multiple stratified analyses, we 
cannot rule out the possibility that our findings may be due to chance. 
In summary, this is the first study of which we are aware to examine the relation of 
menopausal VMS to PMD.  Findings from case-control and prospective studies of a 40-50% 
reduction in breast cancer risk associated with VMS have substantial public health implications, 
including the potential use of VMS as an easily measurable addition to current breast cancer risk 
prediction models.  Our findings of no overall association between VMS and PMD indicate that 
PMD is unlikely to mediate the observed associations between VMS and breast cancer risk.  
However, understanding the mechanism that does link VMS to breast carcinogenesis is critical to 
realizing the impact of VMS as a possible marker of risk.  This study provides evidence that 
severe VMS may affect PMD while symptoms are present.  Further research is necessary to 
confirm these findings and evaluate the extent to which they are informative in explaining the 
observed association between VMS and breast cancer risk.  
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Table 5: Selected patient characteristics measured at baseline (N=833); 
SWAN Mammographic Density Study  
 
 
Study population
N (%)
General characteristics
Age, years: mean (SD) 46.5 (2.68)
BMI, kg/m
2
: mean (SD) 25.4 (5.87)
Underweight/normal: < 25 491 (58.9)
Overweight: 25 - <30 203 (24.4)
Obese: 30+ 131 (15.7)
Race
Caucasian 406 (48.7)
African-American 62 (7.4)
Asian 365 (43.9)
Education level
< High school 136 (16.3)
High school or some college 250 (30.0)
College graduate 222 (26.7)
Post-college 225 (27.0)
Family history of breast cancer (mother or sister) 74 (8.9)
Previous breast biopsy 104 (12.5)
Reproductive history
Menopausal status at baseline
Premenopausal 482 (57.9)
Early perimenopausal 346 (41.5)
Age at menarche (years)
< 12 171 (20.5)
12 234 (28.1)
13 251 (30.1)
14+ 173 (20.8)
Age at first birth (years)
No children 148 (17.8)
< 20 55 (6.6)
20 - 29 395 (47.4)
30+ 234 (28.1)
Number of live births
0 147 (17.6)
1 139 (16.7)
2 354 (42.5)
3+ 192 (23.1)
Hormone therapy use before baseline (ever) 110 (13.2)
Oral contraceptive use before baseline (ever) 604 (72.5)
Percentages may not add to 100% due to unknown values (< 3% for any 
characteristic)
  
Table 6: Regression coefficients and 95% confidence intervals (CI) for percent mammographic density in relation to the presence and 
frequency of self-reported VMS; SWAN Mammography Density Study  
 
 
 
 
  
N
(mammograms) β 95% CI β 95% CI
All women (N=833) 4,746
Non-symptomatic (no VMS) 1,632 Ref Ref Ref Ref
Symptomatic (any VMS) 3,114 -0.69 -1.61, 0.23 -0.47 -1.39, 0.45
Infrequent (1-5 times in past two weeks) 2,410 -0.60 -1.61, 0.41 -0.47 -1.47, 0.53
Frequent (6+ times in past two weeks) 704 -0.97 -2.56, 0.63 -0.47 -2.05, 1.12
HT use during study period (N=250) 1,203
Non-symptomatic (no VMS) 222 Ref Ref Ref Ref
Symptomatic (any VMS) 981 -3.02 -5.59, -0.52 -2.31 -4.83, 0.21
Infrequent (1-5 times in past two weeks) 692 -2.71 -5.47, 0.04 -2.21 -4.90, 0.47
Frequent (6+ times in past two weeks) 289 -3.88 -7.53, -0.23 -2.59 -6.22, 1.04
Model 1
 a
Model 2
 b
a 
Model 1: Age at SWAN visit, education, dietary fat intake, first degree family history of breast cancer, hormone therapy (HT) or oral 
contraceptive (OC) use during study, OC use before baseline, race, age at menarche, and menopausal status
b 
Model 2: Adjusts for variables included in Model 1, plus BMI
  
Table 7: Mean percent mammographic density (PMD) at earliest and latest observation and change in PMD by VMS experience 
among women who naturally transitioned from pre/perimenopausal to postmenopausal (N=426); SWAN Mammographic Density 
Study  
 
 
 
 
  
N Starting PMD
 a
Ending PMD
 a
(women) Mean (SD) % Mean (SD) % Adj. mean %
 b
P value
Non-symptomatic (no VMS) 95 43.5 (22.7) 37.3 (20.2) -5.3 Ref
Symptomatic (any VMS) 331 42.0 (20.1) 35.7 (17.9) -5.4 0.97
Ever, infrequent (1-5 times in past two weeks) 153 41.8 (19.4) 36.5 (18.4) -4.8 0.69
Ever, frequent (6+ times in past two weeks) 178 42.2 (20.8) 35.1 (17.5) -6.1 0.65
a 
Starting PMD is PMD at earliest observation; ending PMD is PMD at latest observation.
b 
Least squares means adjusted for: age at SWAN enrollment, age at first birth, use of HT or OC before baseline, use of HT or OC 
during the study period, BMI at baseline, alcohol use at baseline, menopausal status at baseline, education, dietary fat intake, first degree 
family history of breast cancer, age at menarche, starting PMD, and time difference between starting and ending PMD.
Change in PMD
  
 
Figure 1: Risk estimates and 95% confidence intervals for the association between VMS and percent mammographic density by 
menopausal status and hormone therapy use (N=833) 
HT, hormone therapy; P, progestin; E/P, estrogen/progestin 
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CHAPTER 3 
 
MENOPAUSAL VASOMOTOR SYMPTOMS AND INCIDENT BREAST CANCER RISK 
IN THE STUDY OF WOMEN’S HEALTH ACROSS THE NATION 
3.1 Abstract 
Two case-control studies have reported a 50% decreased breast cancer risk among 
women who experienced menopausal vasomotor symptoms (VMS), but one cohort study found 
no association. VMS may be triggered by declining estrogen levels during menopause, whereas 
elevated estrogen levels have been associated with increased breast cancer risk.  VMS may thus 
be indicative of lower susceptibility to breast cancer.   
We evaluated this relationship in the longitudinal Study of Women’s Health Across the 
Nation (SWAN), which collected annual data on VMS, endogenous hormone levels, and breast 
cancer occurrences in 3,098 women who were pre- or early perimenopausal at enrollment. We 
evaluated the relation of VMS to breast cancer risk using discrete survival analysis.    
Over an average 11.4 years of follow-up, 129 incident breast cancer cases were self-
reported, and approximately 50% of participants experienced VMS.  Symptomatic women had a 
reduced risk of breast cancer compared to non-symptomatic women (OR 0.62, 95% CI 0.39, 
0.99).  The association was stronger in the subgroup of women who fully transitioned to 
postmenopause during follow-up (N=80 cases, OR 0.45, 95% CI 0.26, 0.77). Associations were 
unchanged with adjustment for endogenous hormone levels.  
VMS appear to be a marker of reduced breast cancer risk.  Our findings may suggest a 
more limited role of endogenous hormones in this association than previously hypothesized.  
Future research is needed to understand the biology underlying this relationship. 
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3.2 Introduction 
 Two recent case-control studies found an approximate 50% reduction in breast cancer 
risk for women who reported any menopausal vasomotor symptoms (VMS), defined as hot 
flashes and/or night sweats, prior to their diagnosis compared to those who did not (39, 40). 
However, this provocative result was not supported by a recent, large, prospective cohort study 
(63).  A clear inverse relationship between VMS and breast cancer risk could identify an easily 
measurable factor that may be used to enhance current risk prediction methods.  The inconsistent 
findings from previous studies warrant further prospective investigation of this relationship.  
 An inverse relationship between VMS and breast cancer risk is plausible, given the 
common hormonal mechanisms underlying both VMS and breast carcinogenesis.  Many 
identified breast cancer risk factors are associated with an increased lifetime exposure to sex 
hormones, particularly estrogen, such as early menarche, lower parity, and late age at menopause 
(80, 81).  Further, use of certain exogenous hormone therapies has been shown to increase risk 
(82).  While the exact etiology remains unclear, dramatic fluctuations in endogenous sex 
hormones during the menopausal transition may trigger the onset of VMS (45, 83, 84).  
Exogenous hormone therapy is effective in relieving VMS in many women (46), implying that 
hormone levels may be important to the management and etiology of VMS. 
Prior studies have not adjusted for endogenous sex hormone levels to determine the 
extent to which an association between VMS and breast cancer risk is mediated by hormone 
levels (39, 40, 63).  We prospectively investigated this association in the longitudinal Study of 
Women’s Health Across the Nation (SWAN), a large, racially/ethnically diverse cohort of women 
who have been followed across the menopausal transition, and on whom annual demographic, 
reproductive, and endogenous sex hormone data are available.  We hypothesized that menopausal 
VMS would be associated with reduced breast cancer risk.  We further hypothesized that this 
association would be attenuated after adjustment for endogenous sex hormone levels. 
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3.3 Methods 
3.3.1 Study population 
 The design and recruitment procedure of the SWAN cohort has been described in detail 
elsewhere (54).  Briefly, the study enrolled women from seven locations during 1996-1997, with 
some locations oversampling from different racial groups to create a diverse cohort.  Women 
were aged 42-52 years at enrollment and were pre- or early perimenopausal (i.e., bleeding within 
the last three months).  Women using hormone therapy or oral contraceptives in the prior three 
months were excluded from enrollment, as were women who were pregnant or breastfeeding or 
who did not have an intact uterus and at least one ovary.  In total, 3,302 women were enrolled and 
each provided written consent at the location of recruitment.  All sites obtained institutional 
review board approval for the study protocol.  Annual follow-up visits are on-going and include 
clinical assessments and questionnaires.  Data through follow-up visit 13 are currently available.  
 The current study uses data from the full SWAN cohort.  We excluded 21 women with a 
history of breast cancer at enrollment and a further 183 women who did not participate in any 
follow-up visits beyond the baseline enrollment visit and therefore had no incident breast cancer 
information.  Women who reported that they were pregnant or breastfeeding during the study 
period were excluded for those specific visits (four women, five study visits).  After these 
exclusions, the study population included 3,098 women who contributed data from 34,905 
SWAN visits. 
3.3.2 Vasomotor symptom assessment 
 At the baseline and each annual follow-up visit, SWAN participants reported the 
frequency of VMS in the prior two weeks via a self-administered questionnaire in the language 
appropriate to the participant (English, Spanish, Cantonese, or Japanese) using a standard 
questionnaire.  Questions related to hot flashes and night sweats were worded as follows: 
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“Thinking back over the last two weeks, how often have you had hot flashes or flushes / night 
sweats?”  Response categories were: not at all, 1-5 days, 6-8 days, 9-13 days, every day.  
Consistent with previous analyses in the SWAN cohort (55-57), women who reported any hot 
flashes or night sweats (versus not at all) were classified as being symptomatic of VMS at that 
visit.  Women who reported having hot flashes or night sweats on 6 or more days in the last two 
weeks were classified as being symptomatic of frequent VMS at that visit (38), while women who 
reported having hot flashes or night sweats 1-5 days in the last two weeks were classified as being 
symptomatic of infrequent VMS at that visit. 
3.3.3 Breast cancer assessment 
SWAN participants self-reported cancer history during the baseline enrollment interview.  
At each subsequent follow-up, women were interviewed to assess their medication and health 
status since the previous assessment.  Interviews were administered by trained personnel in the 
language appropriate to the participant (English, Spanish, Cantonese, or Japanese) using standard 
interview questions.  During the interview, women were asked if they had been told that they had 
breast cancer by a health care provider since their last assessment.  Responses were recorded as 
“Yes,” “No,” or “Don’t know.” 
3.3.4 Endogenous sex hormone assessment 
 Endogenous sex hormone and gonadotropin levels (estradiol, E2; sex hormone binding 
globulin, SHBG; follicle stimulating hormone, FSH) were assessed using blood samples collected 
from SWAN participants at each of their annual clinical assessments.  Samples were collected in 
the morning following a 12-hour overnight fast, and were scheduled within 2-5 days of the onset 
of the menstrual cycle (the early follicular phase (EFP)) for pre- and perimenopausal women.  
Two attempts were made to obtain an EFP sample.  If a timed sample could not be obtained, 
usually due to menstrual unpredictability during perimenopause, a random fasting sample was 
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taken within 90 days of the annual SWAN visit date.  Blood samples were refrigerated prior to 
centrifugation, which was performed 1-2 hours after the blood draw (85).  Serum was shipped to 
a central laboratory (SWAN Central Ligand Assay Satellite Services Laboratory, University of 
Michigan, Ann Arbor, MI) for processing.  Assays were performed on the ACS-180 automated 
analyzer (Bayer Diagnostics Corporation); the assay protocol has been described in detail 
elsewhere (86).   All assay processing was blinded with respect to VMS and breast cancer status.  
Inter-assay and intra-assay coefficients of variation (CV) were 6.4% and 10.6% respectively for 
E2, 12.0% and 6.0% respectively for FSH, and 9.7% and 11.3% respectively for SHBG (87). 
3.3.5 Covariate assessment 
Information on covariates was collected during the baseline and annual SWAN follow-up 
visits as part of the clinical assessment or by interviewer- or self-administered questionnaires.  
Demographic and reproductive variables that were considered unchanging in the current analysis 
included: race/ethnicity, education, age at first birth, age at menarche, age at menopause (if 
observed), alcohol consumption, physical activity, active and passive smoking exposure, dietary 
fat and fiber intake, and SWAN site.  Covariates that were considered time-varying and updated 
at each follow-up visit included: menopausal status, body mass index (BMI), parity, family 
history of breast cancer, hormone therapy use, bilateral oophorectomy or hysterectomy, sex 
hormone levels, and cycle day of blood draw for hormone level assessment (day 2-5 versus 
other).  
Menopausal status was classified in accordance with standard SWAN protocol (54): 
women with no change in menstrual regularity over the past year were considered 
premenopausal; women with decreased menstrual regularity who had had a menstrual period in 
the past three months were considered early perimenopausal; women with no menstrual bleeding 
in the 3-11 months before the interview date were considered late perimenopausal; and those with 
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no bleeding in the last 12 months were considered postmenopausal.  Early and late 
perimenopause were collapsed into a single perimenopausal category for this analysis.  Women 
who reported bleeding in the previous 12 months and reported hormone therapy (HT) use in the 
previous year were classified as unknown menopausal status due to HT use for those visits.  
Postmenopausal women remained classified as such if HT use was initiated after the final 
menstrual period.  Women reporting a hysterectomy or bilateral oophorectomy were classified as 
postmenopausal starting at the visit at which the surgery was reported. 
By study design, women were not taking HT at baseline enrollment.  At each follow-up 
interview, women were asked to report the use of estrogen, progestin, or combination 
estrogen/progestin hormone therapy since their last study visit.  When possible, interviewers 
verified medication from the container label.  Lifestyle variables, including alcohol consumption, 
physical activity, smoking, and dietary fat and fiber intake were assessed in accordance with 
previous SWAN publications (38, 57, 62).  Total alcohol consumption was categorized as: <1 
drink/month, 1 drink/month - <2 drinks/week, 2+ drinks/week.  Total physical activity was 
assessed using a continuous variable that incorporated the proportion of the year in which activity 
was performed, a standardized intensity score, and the duration of each bout of activity.  
Development of the physical activity score has been described in detail in previous SWAN 
publications (61).  Smoking was categorized as: never smoked/no passive exposure, never 
smoked/with passive exposure, former smoker, current smoker.  Baseline dietary fat and fiber 
intake were assessed using composite variables that reflected total average consumption based on 
a validated food frequency questionnaire (88). 
3.3.6 Statistical methods 
 After omitting study visits that occurred after a breast cancer diagnosis, a total of 31,712 
observations from 3,098 participants contributed to the current analyses.  Descriptive statistics 
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included means and standard deviations for continuous variables and percentages for categorical 
variables.  We calculated relative risks of breast cancer diagnosis for baseline covariates using 
logistic regression. 
 We assessed the longitudinal association between VMS and incident breast cancer risk 
using logistic regression for discrete survival analyses.  This statistical approach is appropriate for 
data in which the outcome is recorded at discrete time intervals (i.e., SWAN visits) and the actual 
date of the outcome is unknown (89).  Women could contribute varying numbers of observations, 
and observations were omitted after the visit at which the event occurred (i.e., the visit at which a 
breast cancer diagnosis was reported) or continued to the end of the study period if no event 
occurred.  As in other survival analysis approaches, the inclusion of each interval in the dataset 
was conditional on the participant having “survived” past the previous intervals.  To avoid 
temporal concerns with breast cancer treatment affecting VMS, we reverse-lagged the breast 
cancer diagnosis to ensure that only VMS occurring before the diagnosis were considered (e.g., if 
breast cancer was reported at visit 08, VMS and covariate information up to visit 07 were 
included in the analysis). 
 To differentiate between symptomatic and non-symptomatic women, we modeled VMS 
at each study visit as VMS reported at that visit or any prior visit.  Therefore, a woman was 
considered symptomatic from the first visit at which she reported VMS.  Frequent VMS was 
modeled similarly, meaning that a woman was considered symptomatic of frequent VMS from 
the first visit at which frequent VMS was reported.  HT use during the study period was modeled 
in the same fashion.  We developed the multivariable logistic regression models using the method 
of best selection.  Due to the limited number of breast cancer outcomes, we developed a 
parsimonious model, retaining covariates only if they were significant in the model, or if their 
exclusion resulted in a change in the odds ratio for the VMS exposure of 10% or more.  Because 
HT use may act as a confounder or intermediary in the relationship between VMS and breast 
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cancer, we repeated our analysis among women who did not use HT during the study period.  We 
assessed interactions by race/ethnicity, HT use, BMI, and menopausal status using cross-product 
terms.   
 To assess the effect of VMS through the complete menopausal transition on breast cancer 
risk, we performed a secondary analysis of VMS during pre- or perimenopause and 
postmenopausal breast cancer outcomes.  This analysis was restricted to women who fully 
transitioned to postmenopause without surgery during the study period and had a discernable final 
menstrual period because they were not using HT (N=2,468).  Only VMS reported during visits at 
which the woman was pre- or perimenopausal and only breast cancer diagnoses reported during 
visits at which the woman was postmenopausal were included in the analysis.  Women reporting 
pre- or perimenopausal breast cancer were censored at the visit before their breast cancer was 
reported.  A parsimonious multivariable model was built for this analysis using the same 
methodology described above. 
We performed a preliminary analysis to assess the association between sex hormone 
levels and breast cancer risk in our study population.  To evaluate the effect of sex hormone 
levels on the association between VMS and breast cancer, we adjusted for each hormone (E2, 
FSH, SHBG) individually in the multivariable model, as well as for all hormones together.  
Because of the uncertain association between VMS and endogenous hormones and because 
hormone levels fluctuated during perimenopause, we adjusted using several methods: hormone 
level at the current visit, hormone level at the first perimenopausal visit, average hormone level 
and change in hormone level over perimenopausal visits.  Log transformations of hormone values 
were used to satisfy normality assumptions.  All but two women had endogenous hormone data 
for at least one study visit.  However, many women (N=2,579, 83%) had missing hormone data 
during at least one follow-up.  Overall, hormone data were captured for 25,806 of 31,712 study 
visits (81%).  Among visits in which women were pre- or perimenopausal, 63% of hormone data 
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were captured during the first 2-5 days of menses (EFP) and we controlled for cycle day (day 2-5 
or other) in all analyses.  Hormone data were not available at the visit preceding diagnosis for 41 
breast cancer cases, and these cases were excluded from the analysis that adjusted for hormone 
level at the current visit. 
 Due to incomplete data collection, information from the New Jersey location was missing 
for SWAN visits 07, 08, 10, and 11.  This affected 345 study participants, including all Hispanic 
women and one breast cancer case.  We thus performed a sensitivity analysis by excluding all 
women from the New Jersey location and comparing our results to those including these 
participants. 
 All analyses were performed using SAS Version 9.2 (SAS Institute, Cary, North 
Carolina). 
3.4 Results 
  On average, women were approximately 46 years old at enrollment.  The majority was 
Caucasian (47%), with 29% African American, 17% Asian, and 7% Hispanic (Table 8).  Most 
women had completed some college education (76%).  Over an average of 11.7 years of follow-
up, 129 breast cancer cases were self-reported.  Women who reported a breast cancer diagnosis 
during follow-up were more likely to be Caucasian and college-educated.  Overall, VMS were 
reported at 51% of SWAN visits, and the frequency of ever having experienced VMS increased 
from pre- to peri- and postmenopausal (32%, 56%, 52% of visits, respectively).  More African 
American women reported VMS than Caucasian and Hispanic women (63.2% versus 48.8% of 
visits, p<0.01), while fewer Asian women reported VMS than Caucasian and Hispanic women 
(40.6% versus 48.8% of visits, p<0.01). 
We observed that symptomatic women had a 38% reduced risk of breast cancer 
compared to non-symptomatic women (OR = 0.62, 95% CI 0.39-0.99) (Table 9).  This 
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association was modified by race/ethnicity (pinteraction=0.07).  After stratification, we found that the 
relationship between VMS and breast cancer risk was strongest and statistically significant among 
Caucasian women (OR = 0.45, 95% CI 0.22-0.79) (Table 9) and attenuated and non-significant 
among African American and Asian women.  We observed no significant interaction of the 
protective relation of VMS with breast cancer by menopausal status (p=0.22), HT use (p=0.74), 
or BMI (p=0.43).   We found similar results when looking at infrequent versus frequent VMS, 
although confidence intervals were wider due to smaller numbers of breast cancer cases in each 
group. 
In the secondary analysis of pre- and perimenopausal VMS and postmenopausal breast 
cancer (N=2,468 women, 80 cases), we observed that symptomatic women had a significant 55% 
reduction in risk of postmenopausal breast cancer compared to non-symptomatic women (OR = 
0.45, 95% CI 0.26-0.77) (Table 10).  We observed no significant interaction of this protective 
relation by race/ethnicity (p=0.30), HT use (p=0.73), or BMI (p=0.42).  Among women who 
transitioned to postmenopause with no use of HT (N=1,348, 40 cases), results were similar 
although non-significant (OR = 0.50, 95% CI 0.23-1.10) (Table 10). 
 Sex hormone levels were not statistically significantly associated with breast cancer risk 
when adjusted for age, menopausal status, HT use, cycle day (day 2-5 or other), and SWAN visit 
(OR = 1.17, 95% CI 0.91-1.49 for E2; OR = 0.83, 95% CI 0.64-1.09 for FSH; OR = 0.87, 95% CI 
0.60-1.25 for SHBG).  In the longitudinal analysis of VMS and breast cancer risk, adjustment for 
hormone levels did not appreciably change the observed associations for symptomatic women 
compared to non-symptomatic women (Table 11).  These findings were consistent and non-
significant among the 2,049 women with no HT use during the study period (Table 11).  Results 
were less precise but did not otherwise change when the observations of pre- and perimenopausal 
hormone levels that were collected outside the EFP window were excluded from the analysis 
(data not shown).  
 45 
 Results of our analysis did not change after exclusion of women from the New Jersey 
location.  We have therefore presented results from the full study population. 
3.5 Discussion 
 Three prior investigations have examined the relationship between menopausal VMS and 
breast cancer risk (39, 40, 63).  Our findings are consistent with two case-control studies that both 
concluded an approximate 50% reduction in risk for women who experienced VMS at any point 
during the menopausal transition (39, 40).  However, a recent prospective investigation observed 
no association between VMS and breast cancer risk (63).  This study followed 11,297 women 
with a mean age of 47.6 years at enrollment for an average of 13.7 years.  During follow-up, 34% 
reported hot flashes, 26% reported night sweats, and 348 incident breast cancer cases were 
recorded.  Participants were surveyed at three-year intervals and asked to report VMS in the past 
12 months; thus VMS reporting was not captured for two out of every three years, and women 
could contribute a maximum of six observations.  It is likely that some short-term VMS were not 
captured due to the infrequency of the data collection in this study.  This may explain why the 
percentage of women reporting VMS was considerably lower than general estimates of 50-80% 
(35, 36, 38), and may have contributed to the observed null findings, particularly if VMS were 
not recorded during perimenopause when symptoms were most frequent and severe (38).  In 
contrast, our study participants provided annual assessments of VMS over the past two weeks.  
Although some VMS may still have been missed, this protocol was more likely to capture VMS 
at least once during each menopausal stage, and allowed for up to 13 observations per woman. 
 Another unique feature of the present study was the inclusion of a racially/ethnically 
diverse study sample.  We found that the inverse relationship between VMS and breast cancer 
risk was strongest among Caucasian women and weaker among African American and Asian 
women.  After stratification, the number of breast cancer cases in each racial/ethnic subgroup was 
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limited (70, 32, and 26 cases for Caucasian, African American, and Asian, respectively).  Low 
statistical power may thus have contributed to the attenuated results among African American and 
Asian women.  It is interesting, however, that the association between VMS and breast cancer 
risk was strongest among Caucasian women, despite the limited number of cases.  Race/ethnicity 
may influence self-reporting of VMS.  African American women tend to self-report more 
frequent (38) and severe symptoms than Caucasian women (77, 78), although these results have 
not been consistent (90, 91).  In contrast, Asian women have demonstrated less self-reporting of 
VMS than Caucasian women in some studies (79).  Consistent with these findings and previous 
analysis of SWAN VMS data (38), African American women in our study reported more VMS 
and Asian women reported fewer VMS than Caucasian women.  Our findings suggest a 
difference in the effect of VMS on breast cancer risk by race/ethnicity, but it is unclear if this is 
due to true physiological differences, a lack of statistical power after stratification, or racial/ethnic 
variation in the self-reporting of VMS. 
 We anticipated that the association between VMS and breast cancer risk may be related 
to common hormonal etiologies; specifically, we hypothesized that any association would be 
attenuated after adjustment for endogenous sex hormones.  We observed a significant reduction in 
breast cancer risk for women who experienced VMS, but contrary to our expectation, our results 
were unchanged after adjustment for endogenous sex hormones.  Sex hormone levels were not 
statistically significantly associated with breast cancer risk in our study sample, although a 
positive relationship between E2 and breast cancer, and inverse relationships between FSH and 
SHBG and breast cancer are generally supported in the literature (92).  The direction of our 
observed associations was consistent with the literature, and our results could be explained by 
low statistical power due to the small number of breast cancer cases.  Additionally, 37% of pre- 
and perimenopausal hormone data in our study were collected outside the first 2-5 days of menses 
(EFP), although considerable effort was made to collect blood samples during the EFP window 
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(86).  Excess variation in hormone levels may have still further reduced our statistical power, 
despite controlling for cycle day and repeating analyses without observations collected outside 
the EFP window.  
On the other hand, our finding of minimal change in risk with hormone adjustment could 
imply that the mechanism linking VMS to breast cancer is not strongly dependent on endogenous 
hormone levels. While VMS have been associated with estrogen fluctuations during the 
menopausal transition (42), these alone cannot account for the onset of symptoms.  All women 
experience a decline in estrogen during menopause, but not all women experience VMS (47).  
Non-hormonal mechanisms such as changes in skin vasculature and central nervous system 
regulation have been hypothesized to trigger VMS (45, 93).  It is possible that non-hormonal 
mechanisms that are important in both the onset of VMS and breast carcinogenesis could explain 
our results.  Future analyses in larger cohorts are needed to definitively determine the role of 
endogenous hormones in mediating the observed relationship between VMS and breast cancer. 
 Our study was strengthened by the large, prospective, multi-racial/ethnic SWAN cohort 
with annual assessment of demographic, reproductive, and clinical factors over up to 13 years of 
follow-up.  The results of our study must be interpreted within the context of its limitations, 
however.  Both VMS and breast cancer information were self-reported in our analysis.  Previous 
analyses in the SWAN cohort using our definition of presence and frequency of VMS have found 
significant associations between VMS and lower bone mineral density, insulin resistance, and 
subclinical cardiovascular disease (55-57).  Self-report of breast cancer has been shown to be 
valid in large epidemiologic studies (94, 95), but, along with the relatively small number of 
incident breast cancer cases, did limit our capacity to look separately at invasive versus in situ 
disease and at molecular subtypes.   
Establishing VMS as a risk marker for incident breast cancer has considerable public 
health implications.  VMS are easily reportable without invasive or expensive procedures.  An 
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association between self-reported VMS and breast cancer risk could provide additional insight to 
clinicians on the individual breast cancer risk of their patients.  However, a better understanding 
of the mechanisms underlying this association is needed before VMS may be suggested as an 
enhancement to current risk prediction tools.  Our findings may imply that hormonal pathways 
have a lesser role in the association between VMS and breast cancer risk than previously 
hypothesized.  This result strongly justifies the need for future investigations to examine the 
biological mechanisms linking the onset of VMS to breast cancer etiology.  
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Table 8: Selected characteristics measured at baseline by breast cancer diagnosis 
status (N=3,098); SWAN 1996-2013 
No breast cancer 
diagnosis
Breast cancer 
diagnosis
N = 2969 N = 129 OR 95% CI
General characteristics
Age, years: mean (std) 46.3 (2.69) 46.7 (2.73) 1.14 1.02, 1.28
BMI, kg/m
2
: mean (std) 28.2 (7.18) 28.8 (8.24) 1.01 0.96, 1.06
Underweight/normal: < 25 1,201 (40.5) 51 (39.5) Ref Ref
Overweight: 25 - < 30 796 (26.8) 24 (18.6) 0.60 0.24, 1.49
Obese: 30+ 939 (31.6) 52 (40.3) 1.39 0.64, 3.03
Race/ethnicity
Caucasian 1,398 (47.1) 70 (54.3) Ref Ref
African-American 850 (28.6) 32 (24.8) 0.91 0.43, 1.96
Asian 494 (16.6) 26 (20.2) 0.76 0.31, 1.87
Hispanic 227 (7.7) 1 (0.7) 0.35 0.04, 2.97
Education level
< High school 195 (6.6) 4 (3.1) 0.72 0.08, 6.63
High school 517 (17.4) 14 (10.8) Ref Ref
College graduate 957 (32.2) 40 (31.0) 1.56 0.60, 4.02
Post-college 598 (20.2) 33 (25.6) 2.63 1.01, 6.84
Family history of breast cancer (mother or sister) 295 (9.9) 22 (17.1) 1.46 0.66, 3.26
Physical activity score (tertiles)
<7.1 1,083 (36.5) 49 (38.0) Ref Ref
7.1 - <8.5 859 (28.9) 38 (29.5) 0.61 0.28, 1.31
8.5+ 906 (30.5) 37 (28.7) 0.78 0.38, 1.62
Alcohol consumption (past year)
Non-drinkers 1,475 (49.7) 55 (42.6) Ref Ref
Drinkers 1,484 (50.0) 74 (57.4) 1.20 0.65, 2.23
Smoking status
Never smoked / no passive exposure 855 (28.8) 37 (28.7) Ref Ref
Never smoked / passive exposure 841 (28.3) 41 (31.8) 0.65 0.30, 1.40
Former smoker 759 (25.5) 29 (22.5) 0.46 0.20, 1.07
Current smoker 488 (16.4) 20 (15.5) 0.58 0.22, 1.56
Reproductive history
Menopausal status at baseline
Premenopausal 1,555 (52.4) 67 (51.9) Ref Ref
Early perimenopausal 1,345 (45.3) 61 (47.3) 0.66 0.35, 1.22
Age at menarche (years)
< 12 698 (23.5) 39 (30.2) Ref Ref
12 777 (26.2) 29 (22.5) 0.68 0.29, 1.62
13 798 (26.9) 31 (24.0) 0.63 0.26, 1.53
14+ 668 (22.5) 30 (23.3) 1.49 0.67, 3.34
Age at first birth (years)
No children 503 (16.9) 29 (22.5) Ref Ref
< 20 492 (16.6) 12 (9.3) 0.42 0.11, 1.56
20 - 29 1,392 (46.9) 57 (44.2) 0.79 0.33, 1.89
30+ 575 (19.4) 31 (24.0) 1.29 0.51, 3.26
Number of live births
0 501 (16.9) 29 (22.5) Ref Ref
1 504 (17.0) 23 (17.8) 1.05 0.40, 2.78
2 1,002 (33.7) 45 (34.9) 0.94 0.39, 2.28
3+ 955 (32.2) 32 (24.8) 0.62 0.24, 1.65
Hormone therapy use before baseline (ever) 198 (6.7) 12 (9.3) 0.85 0.25, 2.85
Oral contraceptive use before baseline (ever) 2,167 (73.0) 95 (73.6) 1.08 0.54, 2.19
a 
Relative risks adjusted for all selected baseline characteristics
Percentages may not sum to 100% due to missing values
Relative risk
 a
  
Table 9: Odds ratio (OR) and 95% confidence intervals (CI) for the risk of breast cancer diagnosis; 
SWAN 1996-2013 
 
 
 
 
N
(events) OR 95% CI
All women (N=3,098) 129
Non-symptomatic (no VMS) 32 Ref Ref
Symptomatic (any VMS) 97 0.62 0.39, 0.99
Ever, infrequent (1-5 times in past two weeks) 69 0.59 0.36, 0.97
Ever, frequent (6+ times in past two weeks) 28 0.70 0.39, 1.27
White women (N=1,468) 70
Non-symptomatic (no VMS) 22 Ref Ref
Symptomatic (any VMS) 48 0.41 0.22, 0.79
Ever, infrequent (1-5 times in past two weeks) 36 0.41 0.21, 0.81
Ever, frequent (6+ times in past two weeks) 12 0.42 0.18, 0.97
Fully adjusted
 a
a 
Adjusted for age, SWAN visit number, age at first birth, BMI, first degree family history of breast 
cancer, and hormone use during the study period
  
Table 10: Odds ratio (OR) and 95% confidence intervals (CI) for the risk of postmenopausal breast 
cancer diagnosis among women who naturally transitioned to postmenopausal during the study period; 
SWAN 1996-2013 
 
 
 
N
(events) OR 95% CI
All women (N=2,468) 80
Non-symptomatic (no VMS) 24 Ref Ref
Symptomatic (any VMS) 56 0.45 0.26, 0.77
Ever, infrequent (1-5 times in past two weeks) 21 0.39 0.20, 0.75
Ever, frequent (6+ times in past two weeks) 35 0.50 0.28, 0 90
No HT use during the study period (N=1,348) 40
Non-symptomatic (no VMS) 13 Ref Ref
Symptomatic (any VMS) 27 0.50 0.23, 1.10
Ever, infrequent (1-5 times in past two weeks) 12 0.47 0.19, 1.21
Ever, frequent (6+ times in past two weeks) 15 0.52 0.22, 1.23
a 
Adjusted for age at enrollment, SWAN site, age at first birth, BMI at baseline, family history of breast 
cancer, and hormone use during study period
Fully adjusted
 a
HT, hormone therapy
  
Table 11: Odds ratio (OR) and 95% confidence intervals (CI) for the risk of breast cancer diagnosis, adjusted for endogenous hormone 
levels; SWAN 1996-2013 
 
 
 
N
(events) OR 95% CI OR 95% CI OR 95% CI OR 95% CI
All women (N=3,096) 88
Non-symptomatic (no VMS) 26 Ref Ref Ref Ref Ref Ref Ref Ref
Symptomatic (any VMS) 62 0.65 0.39, 1.09 0.68 0.40, 1.13 0.68 0.41, 1.14 0.66 0.40, 1.10
Ever, infrequent (1-5 times in past two weeks) 39 0.57 0.33, 0.97 0.59 0.34, 1.01 0.59 0.34, 1.02 0.57 0.33, 0.99
Ever, frequent (6+ times in past two weeks) 23 0.92 0.50, 1.69 0.98 0.52, 1.82 0.97 0.52, 1.83 0.94 0.50, 1.75
No HT use during the study period (N=2,049) 61
Non-symptomatic (no VMS) 21 Ref Ref Ref Ref Ref Ref Ref Ref
Symptomatic (any VMS) 40 0.71 0.40, 1.26 0.75 0.42, 1.34 0.74 0.41, 1.34 0.72 0.40, 1.30
Ever, infrequent (1-5 times in past two weeks) 28 0.66 0.36, 1.21 0.69 0.37, 1.28 0.69 0.37, 1.28 0.67 0.36, 1.23
Ever, frequent (6+ times in past two weeks) 12 0.87 0.41, 1.86 0.94 0.44, 2.05 0.92 0.42, 2.01 0.92 0.42, 1.97
Adj. for SHBG
a 
Adjusted for age, SWAN visit number, age at first birth, BMI, first degree family history of breast cancer, hormone therapy use during the study 
period, and cycle day of blood draw (day 2-5 or other), and baseline hormone level
Original Model
Fully adjusted
 a
Adj. for E2 Adj. for FSH
E2, estradiol; FSH, follicle stimulating hormone; SHBG, sex hormone binding globulin; HT, hormone therapy
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